This is a double-blind, placebo-controlled, parallel group study to compare the effects of STP7 (mavoglurant) vs placebo control on i.v. cocaine's physiological and subjective effects in non-treatment seeking, cocaine-experienced males or females participants between 18 and 59 years of age.
The primary objective of this study is to determine if there are clinically meaningful interactions between oral STP7 (mavoglurant) treatment concurrent with 20 and 40 mg i.v. cocaine infusions by measuring adverse events and cardiovascular responses including heart rate, blood pressure, and electrocardiogram (including corrected QT interval).
The secondary objectives are:
* To evaluate whether administration of STP7 (mavoglurant) alters the pharmacokinetics of cocaine and/or its major metabolite, benzoylecgonine.
* To determine the pharmacokinetic of STP7 (mavoglurant) administered at a dose of 200 mg twice a day.
* To evaluate whether STP7 (mavoglurant) treatment alters the subjective effects of cocaine measured by Visual Analog Scales (VAS) and Brief Substance Craving Scale (BSCS).

Start Date15 Apr 2024

Sponsor / Collaborator

STALICLA SA

[+1]

NCT05203965

/ RecruitingEarly Phase 1IIT

Functional Neuroimaging of Alcoholism Vulnerability: Probing Glutamate and Reward, Using the mGluR5 Inhibitor Mavoglurant

The purpose of this study is to evaluate the role of Mavoglurant in clarifying the neurobiology of alcoholism risk. This is a one-site, randomized, within subjects, counterbalanced double-blind study of a single dose (200mg) of Mavoglurant and placebo.

Start Date17 May 2022

Sponsor / Collaborator

Yale University

[+1]

100 Clinical Results associated with Mavoglurant

100 Translational Medicine associated with Mavoglurant

100 Patents (Medical) associated with Mavoglurant

Literatures (Medical) associated with Mavoglurant

01 Aug 2025·EUROPEAN JOURNAL OF NEUROLOGY

Efficacy and Safety of Twelve Anti‐Dyskinetic Drugs in Parkinson's Disease: A Bayesian Network Meta‐Analysis of Randomized Controlled Trials

Review

Author: Chen, Xiang‐Ting ; Chen, Wei ; Meng, Chi ; Tao, Pan ; Chen, Fei‐Fei ; Zhang, Qian ; Zhou, Chang‐Qing ; Huang, Jing ; Wen, Si‐Yuan

ABSTRACT:

Background:

No comparative evaluations of anti‐dyskinetic drugs to mitigate levodopa‐induced dyskinesia (LID) and OFF time have been performed; head‐to‐head anti‐dyskinetic trials are unlikely to be funded. We sought to compare the efficacy, tolerability, and safety of 12 anti‐dyskinetic drugs for peak‐dose dyskinesia and OFF time through a Bayesian network meta‐analysis.

Methods:

A network meta‐analysis (NMA) was conducted for randomized controlled trials (RCTs) searched through the databases of MEDLINE, Embase, Cochrane Controlled Register of Controlled Trials from incipiency to January 2025. The main endpoints were the Unified Dyskinesia Rating Scale (UDysRS), modified Abnormal Involuntary Movement Scale, or the Unified Parkinson's Disease Rating Scale IV score for LID and the number of hours of OFF time in a standardized OFF–ON diary for OFF time reduction.

Results:

Twenty‐one RCTs were included in the analysis. The surface under the cumulative ranking curve (SUCRA) indicated that amantadine extended‐release (ER) was associated with the largest improvement in the UDysRS (0.934), followed by amantadine immediate‐release (IR) (0.680). For OFF time reduction, amantadine IR (0.902) and amantadine ER (0.833) were the two best treatments compared with foliglurax (0.526), mavoglurant (0.464) and sarizotan (0.012). Fipamezole ranked first in overall withdrawals (0.812). Amantadine ER ranked first in withdrawals due to adverse events (AEs) and the incidences of AEs (≥ 1 AEs) (0.900 and 0.887).

Conclusions:

Amantadine ER improved dyskinesia significantly versus amantadine IR. Both formulations of amantadine were superior as OFF time‐reducing agents compared to other anti‐dyskinetic drugs, whereas amantadine IR non‐significantly reduced OFF time versus amantadine ER.

01 May 2025·MOVEMENT DISORDERS

Treatment for Dyskinesia in Parkinson's Disease: A Network Meta‐analysis of Randomized Controlled Trials

Article

Author: Su, Dongning ; Zhang, Junjiao ; Feng, Tao ; Yin, Yixuan ; Yan, Rui ; Wan, Zhirong ; Zheng, Xiaoqing ; Cui, Yusha

Abstract:

Background:

Dyskinesia is a motor complication of Parkinson's disease (PD) posing therapeutic challenges. The optimal therapy for dyskinesia in PD has not been identified due to the lack of comprehensive evaluation of treatments.

Objective:

The aim was to compare the efficacy and safety of interventions for alleviating levodopa‐induced dyskinesia in PD.

Methods:

We conducted a Bayesian network meta‐analysis (NMA) by systematically searching PubMed, Web of Science, Embase, Cochrane Library, ClinicalTrials.gov, and EudraCT databases up to April 1, 2024. The primary efficacy outcome was the change in scores on dyskinesia rating scales from baseline.

Results:

The study included 85 randomized controlled trials (RCT) involving 13,826 PD patients, comprising 39 interventions. Nine treatments were significantly more effective in reducing scores on dyskinesia rating scales than control (placebo, sham surgery, sham repetitive transcranial magnetic stimulation, or best medical treatment). Globus pallidus interna deep brain stimulation (GPi‐DBS) had the highest probability to be the most effective (standardized mean difference, 95% credible interval: −1.27, −1.65 to −0.88; surface under the cumulative ranking curve [SUCRA]: 97.4%), followed by levodopa–carbidopa intestinal gel infusion (SUCRA = 89.7%), subthalamic nucleus (STN)‐DBS (SUCRA = 89%), immediate‐release (IR) amantadine (SUCRA = 86.5%), pallidotomy (SUCRA = 84.9%), ADS‐5102 (SUCRA = 82.9%), clozapine (SUCRA = 77.2%), OS320 (SUCRA = 64.8%), and AFQ056 (SUCRA = 54.5%). GPi‐DBS was superior to STN‐DBS, and pallidotomy ranked higher than subthalamotomy. ADS‐5102 and OS320 had higher adverse event (AE) rates compared to control, whereas AFQ056 and ADS‐5102 were linked to more serious AEs.

Conclusions:

This RCT‐based NMA identifies and ranks nine efficacious interventions for dyskinesia in PD. GPi‐DBS may be the most effective therapy for treating dyskinesia, with IR amantadine ranking highest among oral medications. Novel anti‐dyskinetic medications are associated with less‐favorable tolerance profiles. © 2025 International Parkinson and Movement Disorder Society.

02 Apr 2025·Science Translational Medicine

Mavoglurant reduces cocaine use in patients with cocaine use disorder in a phase 2 clinical trial

Article

Author: Gálvez, Bartolomé P. ; Kuper, Enrique I. ; Cha, Jang-Ho ; Walker, Ela ; Dolmetsch, Ricardo ; Gomez-Mancilla, Baltazar ; Berkheimer, Maria ; Dürsteler, Kenneth M. ; Gasparini, Fabrizio ; Gual, Antoni ; Corral, Ricardo M. ; Mosca, Daniel L. ; Pezous, Nicole ; Dumitras, Swati ; Torrens, Marta ; Herdener, Marcus ; Vogel, Marc

Metabotropic glutamate receptor 5 (mGluR5) is involved in cocaine reward processing and addiction. Preclinical studies suggest that blocking this receptor inhibits cocaine self-administration and seeking behavior in rodents. We assessed a selective noncompetitive antagonist of mGluR5 called mavoglurant in a phase 2 randomized, placebo-controlled clinical trial of 68 adults with cocaine use disorder. Study participants were randomly assigned in a 1:1 ratio to an up-titrating schedule of oral mavoglurant twice daily up to 200 mg for 98 days or placebo. The primary end point was the proportion of cocaine use days over the treatment period assessed by a retrospective self-report using Timeline Followback. Secondary end points were urine analysis of the cocaine metabolite benzoylecgonine and alcohol use measured by Timeline Followback assessment. Exploratory end points included testing for cocaine and alcohol metabolites in hair samples. The posterior probability of mavoglurant reducing cocaine use at the end of treatment was ≥99.0% for a treatment difference <0 and ≥36.6% for a treatment difference <−10%. The difference between mavoglurant and placebo was also assessed using analysis of covariance ( P = 0.021). Urine benzoylecgonine concentration was lower in the mavoglurant-treated group versus placebo ( P = 0.025); there was reduced alcohol consumption in the treatment group ( P = 0.072). Seventy-six percent (randomized set) and 79% (safety analysis set) of patients completed the final treatment visit. Adverse events in the treatment group were headache, dizziness, and nausea. In this small and short trial, mavoglurant reduced cocaine and alcohol use in patients with chronic cocaine use disorder.

News (Medical) associated with Mavoglurant

03 Nov 2025

·endpoints.news

Tempero halts substance use disorder drug, is 'assessing strategic alternatives'

A biotech trying to disrupt substance use disorders has paused development of its Phase 2 drug and is looking for alternatives. Tempero Bio, a portfolio company of Aditum Bio, has “temporarily halted advancement of the TMP-301 program and is assessing strategic alternatives,” as of “late October,” according to a quarterly update from Nxera Pharma on Friday. Nxera out-licensed the candidate to Tempero. Tempero declined to comment. Oakland, CA-based Tempero was testing TMP-301, an mGluR5 allosteric modulator, in a Phase 2 trial for alcohol use disorder. That 110-person study is listed as “active, not recruiting” as of a July update to the federal clinical trials database. The startup also completed a Phase 1 drug-drug interaction study for cocaine use disorder. Tempero anticipated having the Phase 2 AUD data around the end of this year, President and Chief Scientific Officer Ricardo Dolmetsch told Endpoints News at the time of the company’s $70 million Series B unveiling in March. Aditum, 8VC and Khosla Ventures contributed to the round. Aditum, led by former Novartis CEO Joe Jimenez, creates single-asset companies to house experimental medicines that it in-licenses from other drug developers. The firm has an R&D team that helps its companies get to clinical proof-of-concept to attract pharma buyers. Eli Lilly bought its obesity biotech Versanis in 2023. Jimenez previously told Endpoints that he doesn’t expect all Aditum offshoots to make it. Renal biotech Anteris shuttered in 2024. Another biotech, Stalicla , is also working on an mGluR5 drug for substance use disorders. Its candidate is called mavoglurant and is derived from Novartis. Meanwhile, Lilly said last week that its protein-based drug brenipatide entered Phase 3 for AUD. Lilly is also running a Phase 2 of its GLP-1/glucagon agonist mazdutide in AUD.

Phase 2Phase 3

30 Jun 2025

·www.globenewswire.com

Stalicla Secures CHF 2 Million Financing Led by Addex Therapeutics to Advance Precision Medicine Neurodevelopmental Disorder Programs

Press Release Stalicla Secures CHF 2 Million Financing Led by Addex Therapeutics to Advance Precision Medicine Neurodevelopmental Disorder Programs Geneva, Switzerland – June 30, 2025 – STALICLA SA, a Geneva-based clinical-stage biotech company pioneering precision medicine for neurodevelopmental and neuropsychiatric disorders, today announced the successful closing of a CHF 2 million financing led by Addex Therapeutics. This financing will sustain operations and program development in neurodevelopmental disorders as Stalicla prepares for its upcoming Series C and the partnering of key programs. This financing underscores investor confidence in Stalicla’s innovative DEPI precision neuro platform and its portfolio of precision autism assets, STP1 and STP2. The company is also progressing its STP7 (mavoglurant) program, the most clinically advanced mGluR5 negative allosteric modulator, having concluded a Phase 3 enabling drug-drug interaction study in October 2024. The Phase 3 development continues to be financed by National Institute of Health-National Institute on Drug Abuse (NIH-NIDA) under a Collaborative Research and Development Agreement.As part of this financing, Tim Dyer has been appointed to the Board of Directors of Stalicla and nominated as Chairman. “This financing is a key step in securing our runway to reach a number of important milestones including our Series C financing,” said Lynn Durham, CEO of Stalicla. “We are grateful for the support from the Addex-led syndicate, which enables us to continue advancing our precision medicine programs and prepare for transformative clinical trials in autism and substance use disorders.” “Stalicla has built a world leading precision medicine neurodevelopment disorder platform and portfolio of clinical stage assets as well as adding tremendous value to their Phase 3 ready substance use disorders asset, STP7,” said Tim Dyer, CEO of Addex and Chairman of Stalicla. “We look forward to supporting Lynn Durham and her team as they bring these important medicines to patients.” About STALICLA: Stalicla SA, a Swiss clinical stage biopharmaceutical company, has raised over $50m to date in equity and more than $30m in non-dilutive funding to propel its mission to transform the landscape of neurodevelopmental disorder (NDD) treatments. The company has established a clinically validated neuro precision development platform that effectively identifies stratified patient subgroups, enabling the advancement of personalized treatment options. Currently, Stalicla is preparing to initiate Phase 2 trials for its leading NDD asset, STP1, along with a second asset, both targeting specific subpopulations within autism. Additionally, STP7 (Mavoglurant) is progressing towards Phase 3 trials, with full funding provided by the US government. For more information, please visit: www.stalicla.com. About Addex Therapeutics Addex is a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders. Addex’s lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is under evaluation for future development in brain injury recovery, including post-stroke and traumatic brain injury recovery. Addex’s partner, Indivior, has selected a GABAB PAM drug candidate for development in substance use disorders and has successfully completed IND enabling studies. Addex is advancing an independent GABAB PAM program for chronic cough. Addex also holds a 20% equity interest in a private spin out company, Neurosterix LLC, which is advancing a portfolio of allosteric modulator programs, including M4 PAM for schizophrenia, mGlu7 NAM for mood disorders and mGlu2 NAM for mild neurocognitive disorders. Addex shares are listed on the SIX Swiss Exchange and American Depositary Shares representing its shares are listed on the NASDAQ Capital Market, and trade under the ticker symbol “ADXN” on each exchange. For more information, please visit www.addextherapeutics.com Contacts: STALICLA SALynn Durham Founder & Chief Executive Officerlynn.durham@stalicla.com Media & InvestorsChris MaggosCohesion Bureauchris.maggos@cohesionbureau.com+41 79 367 62 54 Attachment STALICLA Financing PR_250630_Final

Phase 3Phase 2

30 Jun 2025

·www.globenewswire.com

Addex Leads CHF 2 Million Investment in Stalicla to Advance Precision Medicine in Neuropsychiatric Disorders

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland – June 30, 2025 – Addex Therapeutics (SIX: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced it has led a CHF 2 million investment in Stalicla, a clinical-stage company focused on precision medicine for neurodevelopmental and neuropsychiatric disorders. Stalicla will use the financing to advance its portfolio of autism focused drug candidates, support the partnering of certain assets and its series C financing as well as general corporate activities. As part of the Addex-led financing, Addex CEO, Tim Dyer, has been appointed to Stalicla’s Board of Directors and nominated as Chairman. “This strategic investment underscores Addex’s commitment to advancing innovative treatments for CNS disorders and builds on our 20% equity holding in Neurosterix. Stalicla has built a world leading precision medicine platform in neurodevelopmental disorders, backed by a strong portfolio of clinical-stage assets,” said Tim Dyer, CEO of Addex. “We look forward to providing our industry expertise to support the Stalica team as they bring forward these new treatment options for this underserved patient population.” The investment in Stalicla reinforces Addex’s strategy to support the advancement of precision therapeutics in CNS disorders. Stalicla is preparing to launch Phase 2 trials for its lead autism candidate STP1 and a second asset, both targeting specific subpopulations within autism spectrum disorder (ASD). Stalicla is also advancing its STP7 program (mavoglurant), an mGluR5 NAM, for cocaine use disorders under a Collaborative Research and Development Agreement (CRADA) with the NIH’s National Institute on Drug Abuse (NIDA). This program is the most advanced treatment candidate in development for this indication. “We are delighted to welcome Addex and its syndicate of investors to Stalicla. Addex brings a wealth of life science expertise and we look forward to working with them to build significant value for our shareholders,” said Lynn Durham, CEO of Stalicla. “Stalicla is poised to advance a number of assets into phase 2 clinical studies for subpopulations of patients with ASD and is committed to transforming the lives of these patients and their families.” About StaliclaStalicla SA, a Swiss clinical stage biopharmaceutical company, has raised over $50m to date in equity and more than $30m in non-dilutive funding to propel its mission to transform the landscape of neurodevelopmental disorder (NDD) treatments. The company has established a clinically validated neuro precision development platform that effectively identifies stratified patient subgroups, enabling the advancement of personalized treatment options. Currently, Stalicla is preparing to initiate Phase 2 trials for its leading NDD asset, STP1, along with a second asset, both targeting specific subpopulations within autism. Additionally, STP7 (mavoglurant) is progressing towards Phase 3 trials, with full funding provided by the US government. About Addex TherapeuticsAddex is a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders. Addex’s lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is under evaluation for future development in brain injury recovery, including post-stroke and traumatic brain injury recovery. Addex’s partner, Indivior, has selected a GABAB PAM drug candidate for development in substance use disorders and has successfully completed IND enabling studies. Addex is advancing an independent GABAB PAM program for chronic cough. Addex also holds a 20% equity interest in a private spin out company, Neurosterix LLC, which is advancing a portfolio of allosteric modulator programs, including M4 PAM for schizophrenia, mGlu7 NAM for mood disorders and mGlu2 NAM for mild neurocognitive disorders. Addex shares are listed on the SIX Swiss Exchange and American Depositary Shares representing its shares are listed on the NASDAQ Capital Market, and trade under the ticker symbol “ADXN” on each exchange. For more information, visit www.addextherapeutics.com Contacts: Tim Dyer Chief Executive Officer Telephone: +41 22 884 15 55 PR@addextherapeutics.com Mike Sinclair Partner, Halsin Partners +44 (0)7968 022075 msinclair@halsin.com Addex Forward Looking Statements:This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements about the intended use of proceeds of the offering. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release, are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to market conditions. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in Addex Therapeutics’ Annual Report on Form 20-F, prospectus and other filings that Addex Therapeutics may make with the SEC in the future. Any forward-looking statements contained in this press release represent Addex Therapeutics’ views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Addex Therapeutics explicitly disclaims any obligation to update any forward-looking statements.

Phase 2Phase 3

100 Deals associated with Mavoglurant

External Link

KEGG	Wiki	ATC	Drug Bank
-	Mavoglurant	-	DB13004

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Substance Abuse	Phase 3	United States	National Institute on Drug Abuse	08 Mar 2023
Substance Abuse	Phase 3	United States	STALICLA SA	08 Mar 2023
Fragile X Syndrome	Phase 3	United States	Novartis Pharmaceuticals Canada, Inc.	01 Nov 2011
Fragile X Syndrome	Phase 3	Australia	Novartis Pharmaceuticals Canada, Inc.	01 Nov 2011
Fragile X Syndrome	Phase 3	Belgium	Novartis Pharmaceuticals Canada, Inc.	01 Nov 2011
Fragile X Syndrome	Phase 3	Denmark	Novartis Pharmaceuticals Canada, Inc.	01 Nov 2011
Fragile X Syndrome	Phase 3	France	Novartis Pharmaceuticals Canada, Inc.	01 Nov 2011
Fragile X Syndrome	Phase 3	Germany	Novartis Pharmaceuticals Canada, Inc.	01 Nov 2011
Fragile X Syndrome	Phase 3	Israel	Novartis Pharmaceuticals Canada, Inc.	01 Nov 2011
Fragile X Syndrome	Phase 3	Italy	Novartis Pharmaceuticals Canada, Inc.	01 Nov 2011

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03327792 (CTgov)	Phase 1	Psychedelic	34	Mavoglurant (200 mg Mavoglurant)	uockayevcy = ugjzhuqjke gkdnqxaniw (kzicygiodp, osgrotysnm - ofmcdmlbti) View more	-	06 Aug 2024
				Placebo (Placebo)	uockayevcy = kznakoreed gkdnqxaniw (kzicygiodp, dgoaxugedi - asnyhrwtnr) View more
NCT02920892 (FX-LEARN, CTgov)	Phase 2	Fragile X Syndrome	110	placebo+AFQ056 (Placebo Comparator: Double-Blind Placebo With Language Intervention)	ylhoejdyko(nhaskvvhdm) = umcxnnsmen fwrcnrzwlu (athrergznb, kggsqamoto - fiudxslkih) View more	-	10 Oct 2023
				AFQ056 (Experimental: Double-Blind AFQ056 With Language Intervention)	ylhoejdyko(nhaskvvhdm) = igfuzdsrwl fwrcnrzwlu (athrergznb, ehisezqpoe - daitssdpyw) View more
NCT03242928 (CTgov)	Phase 2	Cocaine-Related Disorders \| Systemic Carnitine Deficiency	68	AFQ056 (AFQ056)	zbqmdeltbq(jgwobqbvzi) = ylmdwvxwuv wvedmtydhq (kyrssvbiwe, 0.027) View more	-	04 Feb 2021
				Placebo (Placebo)	zbqmdeltbq(jgwobqbvzi) = pavfphrqmu wvedmtydhq (kyrssvbiwe, 0.024) View more
NCT01348087 (Pubmed \| Sci Rep) Manual	Phase 2	Fragile X Syndrome	267	mavoglurant	molwovxeyl(pilbgllvev) = gbxfesvlsq fsmlwjmqbz (vawrqowrfa ) View more	Negative	19 Nov 2018
NCT01813019 (Pubmed \| Adv Ther) Manual	Phase 2	Obsessive-Compulsive Disorder	50	mavoglurant	uewxwuajac(qmhkswjlus) = ihfvdynbbz imkrqpwsxn (rlmmempnej ) View more	Negative	01 Feb 2017
				Placebo	uewxwuajac(qmhkswjlus) = evdjgspnqh imkrqpwsxn (rlmmempnej ) View more
NCT01813019 (CTgov)	Phase 2	Obsessive-Compulsive Disorder	50	Placebo (Placebo)	lrwvkemghz(olcfndhpkh) = yplhptusvo nushokmdtp (izgqbinzhd, 1.78) View more	-	21 Jul 2016
				AFQ056 (AFQ056)	lrwvkemghz(olcfndhpkh) = gpksoivlly nushokmdtp (izgqbinzhd, 1.75) View more
NCT01385592 (Pubmed) Manual	Phase 2	Dyskinesia, Drug-Induced \| Parkinson Disease	-	Mavoglurant	lrkndtjfhf(mrwsvpviej) = did not reach statistical significance hhnqmpwjde (dqovczgxel )	Negative	01 Jul 2016
				Placebo
NCT01253629 (Pubmed \| Sci Transl Med) Manual	Phase 2	Fragile X Syndrome	314	Mavoglurant	cuuvqdnrqu(cuinvuvkuc) = Neither of the studies achieved mletxkuasz (nqznqkkzrr )	Negative	13 Jan 2016
				Placebo
NCT01357239 (CTgov)	Phase 2	Fragile X Syndrome	139	Placebo	gbjmqamfzb(intrfvmmah) = bmvsyqdxnq hehhyyodyq (saczcrqfvp, 3.88) View more	-	12 May 2015
NCT01019473 (Pubmed \| Mov Disord) Manual	Phase 2	Chorea \| Huntington Disease	42	AFQ056	bdntoegalh(ynujlhislk) = no improvement fqawtstjei (bwdxpxwskc ) View more	Negative	01 Mar 2015
				Placebo

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis